Carmen Pilar Simeón i Aznar Instituciones de las que forman parte Investigador/a principal Enfermedades Sistémicas Vall Hebron Institut de Recerca Email Carmen Pilar Simeón i Aznar Email Instituciones de las que forman parte Investigador/a principal Enfermedades Sistémicas Vall Hebron Institut de Recerca
Líneas de investigación Protein expression of small collagenase 3 and leucine-rich proteoglycans in cutaneous tissue of patients with diffuse scleroderma. This study, carried out along with researchers from the Hospital del Mar and from the "Institut Municipal d'Investigació Mèdica", aims at correlating the expression of SLRPs and MMP-13 with the severity of cutaneous involvement, hand dysfunctional capacity, capillaroscopy patterns, and cutaneous ultrasonography of patients affected with diffuse scleroderma in different evolutive stages of the disease. IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla Specific Antinuclear antibodies of scleroderma as markers for different clinical patterns. We want to establish the relationship between the presence of specific autoantibodies for scleroderma (anti-centromere, anti-topoisomerase 1, anti-polymerase III, anti-U3 RNP, Anti-Th/To, Anti-Pm/Scl, anti-Ku) with the different demographic and clinical features as well as with the disease prognosis. IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla Protein expression of small collagenase 3 and leucine-rich proteoglycans in cutaneous tissue of patients with diffuse scleroderma. This study, carried out along with researchers from the Hospital del Mar and from the "Institut Municipal d'Investigació Mèdica", aims at correlating the expression of SLRPs and MMP-13 with the severity of cutaneous involvement, hand dysfunctional capacity, capillaroscopy patterns, and cutaneous ultrasonography of patients affected with diffuse scleroderma in different evolutive stages of the disease. IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página 3 Página 4 Página actual 5
